A HER2xPRLR bsADC with a DM1 payload (DAR = 3.3) and non-cleavable linker induced HER2 degradation and exhibited increased potency over parental ADC monotherapy and combination therapy in BC cells [210]. The gene discussed is ERBB2; the disease is breast cancer.